Eledon Pharmaceuticals, Inc.
General ticker "ELDN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $219.6M (TTM average)
Eledon Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 32.9%.
Estimated limits based on current volatility of 4.1%: low 2.21$, high 2.40$
Factors to consider:
- Total employees count: 33 (+6.5%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Inability to raise capital, Failure to achieve profitability, Regulatory and compliance, Clinical trial failure, Cybersecurity threats
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.97$, 2.53$]
- 2026-12-31 to 2027-12-31 estimated range: [0.87$, 2.22$]
Financial Metrics affecting the ELDN estimates:
- Positive: with PPE of -3.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Investing cash flow per share per price, % of 8.47 > 2.08
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: 42.26 < Shareholder equity ratio, % of 47.98 <= 49.86
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -21.25
- Positive: Interest expense per share per price, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ELDN quotes
Long-term ELDN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.67MM | $3.92MM | $4.22MM |
| Operating Expenses | $45.67MM | $74.50MM | $87.47MM |
| Operating Income | $-43.00MM | $-70.58MM | $-83.25MM |
| Non-Operating Income | $-73.54MM | $34.82MM | $37.67MM |
| R&D Expense | $30.31MM | $51.96MM | $66.27MM |
| Income(Loss) | $-116.54MM | $-35.75MM | $-45.58MM |
| Taxes | $0.00MM | $0.43MM | $0.04MM |
| Net Income(Loss)* | $-116.54MM | $-36.18MM | $-45.62MM |
| Stockholders Equity | $7.21MM | $118.14MM | $81.08MM |
| Assets | $89.07MM | $177.41MM | $169.01MM |
| Operating Cash Flow | $-39.53MM | $-47.27MM | $-62.34MM |
| Investing Cash Flow | $-45.29MM | $-70.31MM | $10.79MM |
| Financing Cash Flow | $33.02MM | $133.52MM | $53.81MM |
| Earnings Per Share** | $-4.73 | $-0.75 | $-0.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.